An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Background Metabolic abnormal conditions, such as diabetes and high triglycerides (TGs), are commonly associated with nonalcoholic fatty liver disease (NAFLD). Currently, there is no approved pharmacotherapy for NAFLD. Saroglitazar, the world’s first approved dual peroxisome proliferator-activated r...

Descripción completa

Detalles Bibliográficos
Autor principal: Mitra, Asis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413319/
https://www.ncbi.nlm.nih.gov/pubmed/32782883
http://dx.doi.org/10.7759/cureus.9065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413319/
https://www.ncbi.nlm.nih.gov/pubmed/32782883
http://dx.doi.org/10.7759/cureus.9065

Ejemplares similares